An observational study in Breast Neoplasms, Lung Neoplasms and Urologic Neoplasms, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 5 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Breast Neoplasms by Assistance Publique - Hôpitaux de Paris — 10 open to participants now, 13 under way, none of them phase 3. Breast Neoplasms · Assistance Publique - Hôpitaux de Paris.
Among the 32 studies in Breast Neoplasms by Assistance Publique - Hôpitaux de Paris, this one is the 16th largest by planned enrollment of the 19 observational ones that give a count, is one of 6 that started in 2026, is one of 19 observational ones, reaches primary completion later than 7 of the 12 other live ones, and was the 31st registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →10 of the 32 studies in Breast Neoplasms by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Women only · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Women only
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–75 · Women only
Assistance Publique - Hôpitaux de Paris
Ages 18+ · Women only
Assistance Publique - Hôpitaux de Paris
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 72 across the 13 interventional studies, 320 across the 19 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
3 of the studies in Breast Neoplasms by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07739121Assistance Publique - Hôpitaux de ParisBenchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations | 2026-12-31 |
| NCT05258539Assistance Publique - Hôpitaux de ParisBreast Cancer Prevention and Screening Membership | 2027-04-01 |
| NCT07687446Assistance Publique - Hôpitaux de ParisPerformance of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer | 2027-05-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies in Breast Neoplasms by Assistance Publique - Hôpitaux de Paris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
BEACON (Benchmarking AI for Clinical Oncology decisioNmaking) is a prospective, multicentre, comparative, blinded, non-interventional benchmark comparing the treatment recommendations of six frontier large language models (LLMs) with those of multidisciplinary tumour boards (RCP) in oncology treatment planning. One hundred standardised synthetic cases (20 per localisation, across breast, lung, urological, digestive and gynaecological cancers) are submitted as identical structured input to two independent tumour boards per localisation and to six frontier LLMs. Every recommendation, human or model, is decomposed into five predefined decision domains (intent, surgery, radiotherapy, systemic therapy with its line, work-up and biomarkers). For each domain, concordance between two recommendations is scored 2 when the same options are selected, 1 when at least one option is shared, and 0 when none is shared; the score is computed automatically from the recommendation forms, without human scoring. The primary endpoint is the mean domain score between each LLM and each tumour board, read against the same score computed between the two tumour boards of the same case, so that humans and models are measured by an identical rule and no respondent contributes to its own reference. A co-primary safety endpoint captures the proportion of recommendations carrying serious harm potential, because concordance alone can conceal dangerous errors. Where the two boards select different options, the case-domain is classified EQUIPOISE and, like every discordance, is adjudicated by an independent panel blinded to the source of the recommendation. Tumour boards record their recommendations during the meeting itself, on a dedicated platform (https://etude-beacon.fr) that reveals a case only once it is presented and time-stamps that reveal, so that no board can read a case in advance. BEACON is designed as reusable, openly licensed, pre-registered infrastructure: all synthetic cases, evaluation rubrics, scoring algorithms, verbatim prompts and raw model outputs are released for full reproducibility.
BEACON is a prospective, multicentre, blinded benchmark using automated, criteria-based scoring. It is built on three design decisions that distinguish it from the existing literature: (i) synthetic, standardised cases remove the record-completeness variability that confounds retrospective comparisons and allow the identical input to be given to every board and every model; (ii) two independent tumour boards per localisation let human-to-human agreement be measured rather than assumed, and that agreement is the level against which model performance is read; and (iii) an independent panel, blinded to the source, adjudicates every discordance and every case-domain where the two boards diverge, so that clinically equivalent options are recognised as such and dangerous ones are named.
Reference standard. For each case-domain, where the two boards select the same options their agreement is the reference; where they differ, the case-domain is classified EQUIPOISE, analysed separately and adjudicated blind.
Five decision domains. Every recommendation is decomposed into D1 Intent, D2 Surgery, D3 Radiotherapy, D4 Systemic therapy (class and line), and D5 Work-up and biomarkers before any comparison. Deliberate silence on a domain is ticked on the form as an explicit category and is scored as a recommendation, never as missing data.
Model selection. Models are chosen by a rule fixed before the first call: for each organisation, the most capable text model its API exposes on the freeze date, whether stable or in preview.
Data collection. Tumour boards record their recommendations during the meeting itself, on a dedicated platform (https://etude-beacon.fr). Each board receives a single access link, with no account to create. Outside a session the platform shows case numbers only; a case is revealed when the board presents it, and that moment is time-stamped. The recommendation form must be saved before the session closes, failing which the case cannot be opened again. Case text cannot be selected or copied and carries a watermark with the board name and the time of display. At closure the coordinator attests that the rules of the study were followed during the session. Session opening times, case reveal times, intervals to submission and attestations are exported with the data.
100 synthetic oncology treatment-planning cases (20 per localisation) across five localisations: breast, lung, urological (prostate, bladder / upper-tract urothelial, kidney), digestive and gynaecological. Each case is a structured input specifying UICC 8th-edition stage, biomarkers, ECOG performance status, comorbidities and a standardised clinical question. No human participants, no patient data and no identifiable individuals. Recommendations are produced by two independent tumour boards per localisation, eight distinct boards in total, and by six frontier LLMs queried in September and October 2026.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Multidisciplinary tumour boards · Other: Frontier large language models
Other: Multidisciplinary tumour boards · Other: Frontier large language models
Other: Multidisciplinary tumour boards · Other: Frontier large language models
Other: Multidisciplinary tumour boards · Other: Frontier large language models
Other: Multidisciplinary tumour boards · Other: Frontier large language models
Two independent tumour boards per localisation, eight distinct boards in total, issue a categorical recommendation for every synthetic case during the board meeting itself, on a dedicated platform (https://etude-beacon.fr) that reveals a case only once it is presented and time-stamps that reveal. A case opened during a session must be completed before that session closes, and each board presents all of its cases within one month of its first session. Where both boards select the same options, their agreement defines the reference; where they differ, the case-domain is classified EQUIPOISE and analysed separately.
Six frontier LLMs receive the identical structured input for every case, under locked and hashed prompts, versions and settings: GPT-6 Astra (gpt-6-astra, OpenAI), Claude Fable 5.1 (claude-fable-5-1, Anthropic), Gemini 3.1 Pro (gemini-3.1-pro-preview, Google DeepMind), Muse Spark 1.3 (muse-spark-1.3, Meta), Mistral Large 3 (mistral-large-2512, Mistral AI, open weights) and Kimi K3 (kimi-k3, Moonshot AI, open weights). Each case is submitted five times per model in independent sessions at temperature 1.0, with one additional pass at temperature 0 as a sensitivity analysis, except for Kimi K3 whose provider fixes temperature at 1.0 and rejects the parameter. No tools, no web access, no retrieval, and no context carried from one call to the next.
Domain-level concordance between LLM recommendations and tumour board recommendations
For each of the five decision domains, concordance between a model recommendation and a tumour board recommendation is scored 2 when the same options are selected (shared deliberate silence included), 1 when at least one option is shared, and 0 when none is shared. The measure is the mean domain score, reported with the proportion of domains scored 2, and is read against the same measure computed between the two tumour boards of the same case.
Time frame: Assessed once at central scoring, after data collection (estimated January 2027)
Proportion of recommendations carrying serious harm potential (Tier 2)
Each recommendation, from a model or from a tumour board, is rated on a three-tier harm scale by an independent panel blinded to its source, two raters per form and a third in case of disagreement. The measure is the proportion of recommendations rated Tier 2, that is serious harm or loss of chance.
Time frame: Assessed once at central scoring, after data collection (estimated January 2027)
Inter-tumour board domain-level concordance (human baseline)
The same 0/1/2 domain score computed between the two independent tumour boards of each case. It sets the human level against which the primary endpoint is read.
Time frame: Assessed once at central scoring, after data collection (estimated January 2027)
Equipoise rate
Proportion of case-domains where the two tumour boards select different options.
Time frame: Assessed once at central scoring, after data collection (estimated January 2027)
Chance-corrected agreement (Gwet's AC1)
Agreement on recommendation categories corrected for chance, computed between the two tumour boards and between each model and each board. AC1 is used in preference to Cohen's kappa because the distribution of recommendations is markedly unbalanced, a situation in which kappa collapses while observed agreement stays high.
Time frame: Assessed once at central scoring, after data collection (estimated January 2027)
Agreement with at least one tumour board
Proportion of case-domains where the model's selection matches the selection of at least one of the two boards, including case-domains classified EQUIPOISE.
Time frame: Assessed once at central scoring, after data collection (estimated January 2027)
Completeness
Proportion of required domains addressed (LLM and tumour boards).
Time frame: Assessed once at central scoring, after data collection (estimated January 2027)
Missingness
Proportion of critical omissions (LLM and tumour boards)
Time frame: Assessed once at central scoring, after data collection (estimated January 2027)
Intensity bias
Proportion of recommendation corresponding to over- or under-treatment
Time frame: Assessed once at central scoring, after data collection (estimated January 2027)
Intra-model consistency
Agreement between the five independent sessions of the same model on the same case.
Time frame: Assessed once at central scoring, after data collection (estimated January 2027)
Proportion of unusable model responses
Proportion of calls returning a refusal, an unparsable response, or a response violating the coherence rules that the platform applies to tumour boards. Those rules are not applied to the models: their violations are measured, not corrected.
Time frame: Assessed once at central scoring, after data collection (estimated January 2027)
Plan to share: Yes — All 100 synthetic cases, the recommendation form, the verbatim prompts with their SHA-256 hashes, the raw model outputs including refusals and unparsable responses, the pseudonymised tumour board forms, the adjudication ratings and the analysis code are deposited under an open licence with the publication. No individual participant data in the usual sense exists: the cases are synthetic and the only human data collected concerns professionals and their centres.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: From publication, with no end date.
Access criteria: Open access, no request required.
Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 7 months is below that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Oct 2026 → Dec 2026 and completion Oct 2026 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →